At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
PF-00232798 +5 moredrug
Likely dose
PF-00232798 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study In Asymptomatic Hiv-Infected Patients To Investigate The Pharmacodynamics, Pharmacokinetics, Safety And Toleration Of PF-00232798
In Brief
A Phase 2 clinical trial evaluating PF-00232798 for HIV. Completed, enrolled 43 participants across 2 sites.
Detailed Summary
To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJul 2007
Primary CompletionSep 2008
TodayJul 2026
First PostedJul 3, 2007
Enrollment StartJun 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.0 years ago
Interventions
PF-00232798drug
Solution, 20 mg. once daily, 10 days
PF-00232798drug
Solution, 150 mg. once daily, 10 days
PF-00232798drug
Solution, 5 mg. once daily, 10 days
PF-00232798drug
Solution, 40 mg. once daily, 10 days
PF-00232798drug
Solution, 300 mg. once daily, 10 days
PF-00232798drug
Solution, 400 mg. once daily, 10 days